← Leaderboards
H Steve White
University Of Utah
$4,795,912
Attributed
$5,381,770
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,381,770 · 5
By mechanism
U01$3,446,499 · 1
R01$886,535 · 1
R33$383,265 · 1
R21$380,290 · 1
R61$285,181 · 1
Top collaborators
- Karen S Wilcox3 shared
- Tawfeeq Shekh-Ahmad1 shared
Most similar at University Of Utah
Same institution · by research overlap
- Robert S Fujinami$9,893,456
- Ana Beatriz De Paula E Silva$1,117,112
- Laura Ann Bell$306,022
- Ikuo Tsunoda$524,766
- Daria Nesterovich Anderson$194,430
Others in their field
Top investigators on “Epilepsy”
- Karen Wilcox · University Of Utah$40,784,208
- Mark J Daly · Broad Institute, Inc.$39,233,325
- Wayne N. Frankel · Jackson Laboratory$37,394,025
- Shlomo Shinnar · Montefiore Medical Center (Bronx, Ny)$34,999,274
- Christopher A Walsh · Beth Israel Deaconess Medical Center$34,874,606
- Stacey Gabriel · Massachusetts Institute Of Technology$34,637,180
Research focus
EpilepsyRattusBrainSeizuresChronicPharmaceutical PreparationsPlayAnimalsAnticonvulsantsPersonsBiological AvailabilityNeuraxisNovel StrategiesPerformanceBehavioralLeadMolecular TargetBlood - Brain Barrier AnatomyAffectInjection Of Therapeutic AgentDoseAnimal ModelDrug InteractionsCognitive
Grant awards (12)
Evaluating the disease modifying properties of dimethyl fumarate (DMF) for the prevention and treatment of pharmacoresistant epilepsy$383,265
R33 · FY2025 · NS · contact PI
Evaluating the disease modifying properties of dimethyl fumarate (DMF) for the prevention and treatment of pharmacoresistant epilepsy$285,181
R61 · FY2024 · NS · contact PI
Development of a galanin-based therapy for the treatment of refractory epilepsy$1
U01 · FY2014 · NS · contact PI
Development of a galanin-based therapy for the treatment of refractory epilepsy$878,606
U01 · FY2013 · NS · contact PI
A Novel Mouse Model of Temporal Lobe Epilepsy$288,535
R01 · FY2013 · NS
Development of a galanin-based therapy for the treatment of refractory epilepsy$861,472
U01 · FY2012 · NS · contact PI
A Novel Mouse Model of Temporal Lobe Epilepsy$299,000
R01 · FY2012 · NS
Development of a galanin-based therapy for the treatment of refractory epilepsy$964,863
U01 · FY2011 · NS · contact PI
A Novel Mouse Model of Temporal Lobe Epilepsy$299,000
R01 · FY2011 · NS
Development of a galanin-based therapy for the treatment of refractory epilepsy$741,557
U01 · FY2010 · NS · contact PI
Evaluation of models of pharmacoresistant epilepsy.$172,859
R21 · FY2005 · NS
Evaluation of models of pharmacoresistant epilepsy$207,431
R21 · FY2004 · NS